La Jolla Pharmaceutical Co., of San Diego, initiated a phase IIb trial of GCS-100 to treat advanced chronic kidney disease (CKD) caused by diabetes. The double-blind, multicenter, placebo-controlled, randomized trial will evaluate the galectin-3 inhibitor in diabetic patients with stage 3b or 4 CKD.